Loading...
NPI 1801197256 · Santa Fe, NM · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Esoterix Genetic Laboratories, LLC is a clinical medical laboratory provider located in Santa Fe, New Mexico. This profile covers 4 Medicare and 33 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Esoterix Genetic Laboratories, LLC |
| Address | 2000 Vivigen Way |
| City | Santa Fe |
| State | NM |
| ZIP | 87505 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 16, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $6.7M |
| Medicare | $1.5K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 82164 | The lab analyst performs a measurement of this enzyme in serum or plasma. The analyte acts to convert angiotensin I to angiotensin II. | 50 | $10 | $700 |
| 82963 | The lab analyst measures the beta glucosidase level, which can be in a variety of specimen types, but analysts primarily use specimens of tissue cells called fibroblasts or white blood cells. Beta… | 20 | $20 | $380 |
| 84060 | The lab analyst measures the total acid phosphatase, most commonly in a serum specimen. The liver, bone, spleen, kidneys, and also the prostate in males are the primary production sites for the… | 50 | $10 | $360 |
| 84155 | The lab analyst performs the technical lab test to quantitate total protein in a serum, plasma, or whole blood specimen using one of several assay methods, excluding refractometry. Total protein is a… | 20 | $1 | $70 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
33 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 7,770 | $140 | $1.1M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 2,750 | $230 | $644.4K |
| 84702 | The lab analyst performs the technical lab test to measure the amount of hCG, also known as beta hCG, in blood to confirm or monitor pregnancy, or to diagnose certain tumors of the testes or ovaries. | 79,170 | $10 | $633.4K |
| 88267 | The analyst performs chromosome analysis of cells from amniotic fluid cells or chorionic villus, counts 15 cells, and prepares one karyotype, with banding. Amniotic fluid surrounds a developing fetus… | 6,850 | $90 | $596.1K |
| 82105 | The lab analyst measures the quantitative level of the alpha–fetoprotein. This glycoprotein is produced early in fetal life, and a variety of tumors can also produce it later in life. | 60,960 | $10 | $548.6K |
| 82677 | The lab analyst measures the level of estriol, a weak estrogen hormone, which is usually in high concentrations only during pregnancy. | 35,570 | $10 | $498K |
| 88235 | The lab analyst prepares a tissue culture for nonneoplastic disorders using amniotic fluid or chorionic villus cells. In this process, fetal cells in amniotic fluid, which is fluid surrounding the… | 7,730 | $60 | $479.4K |
| 84163 | The lab analyst performs a test to quantitate pregnancy associated plasma protein A, PAPPA, which is a test labs typically perform in the first trimester of pregnancy. Clinicians commonly use the… | 51,170 | $10 | $409.3K |
| 88262 | The analyst performs a chromosome analysis, a test that examines a person’s genetic material for abnormalities, counts 15 to 20 cells, and makes two karyotypes with banding, which are pictures of the… | 5,070 | $70 | $334.5K |
| 86336 | The lab analyst performs a test to identify the levels of inhibin A, typically in a pregnant patient’s serum, to determine the risk for Down syndrome in the fetus. The specimen is blood which the lab… | 35,210 | $10 | $316.9K |
Showing 1–10 of 33
How this provider's Medicaid billing volume and revenue compare to other New Mexico providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Mexico median
33 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 88267 | The analyst performs chromosome analysis of cells from amniotic fluid cells or chorionic villus, counts 15 cells, and prepares one karyotype, with banding. Amniotic fluid surrounds a developing fetus… | 1 | 10 | 6,850 | $90 | $597.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 63 | 80 | 3,340 | $60 | $595K |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 1 | 10 | 820 | $230 | $553.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 28 | 40 | 880 | $80 | $527.4K |
| 88235 | The lab analyst prepares a tissue culture for nonneoplastic disorders using amniotic fluid or chorionic villus cells. In this process, fetal cells in amniotic fluid, which is fluid surrounding the… | 1 | 10 | 7,730 | $60 | $482.9K |
| 88262 | The analyst performs a chromosome analysis, a test that examines a person’s genetic material for abnormalities, counts 15 to 20 cells, and makes two karyotypes with banding, which are pictures of the… | 1 | 10 | 5,070 | $70 | $333.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 48 | 50 | 530 | $90 | $323.8K |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 1 | 10 | 340 | $240 | $260K |
| 88230 | The lab analyst performs a procedure to grow a tissue culture for lymphocytes in a nonneoplastic disorder, typically using blood. Lymphocytes, a type of white blood cell, function as part of the… | 1 | 10 | 4,150 | $60 | $229.6K |
| 88271 | The analyst performs a molecular cytogenetic test using a DNA probe method, such as FISH, fluorescence in situ hybridization, to test cells for genetic abnormalities. | 1 | 10 | 5,240 | $40 | $217.2K |
Showing 1–10 of 33
Other providers in the same ZIP code as Esoterix Genetic Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.